Incyte (INCY) Misses Q2 EPS by 3c, Sales Beat; Raises FY17 Jakafi Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
August 1, 2017 7:00 AM EDT$276 million of 2017 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 33 percent growth over the same period last year Proof-of-concept data for the combination of epacadostat plus PD-1 inhibition presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2017 across multiple tumor types; expanded Phase 3 program on track for planned initiation in 2017 Multiple product candidates in late-stage clinical development illustrates transformational growth potential of Incytes portfolio
Conference Call and Webcast Scheduled Today at 10:00 a.m. ET
WILMINGTON, Del.--(BUSINESS... More
